Solvay

Solvay S.A. is a Belgian multidisciplinary chemical company. Solvay's product range is used in aircraft, automotive, agriculture, food industry, construction, mining and many other fields.

It has its headquarters in Brussels, Belgium.

History

2023

Belgian chemicals giant Solvay splits into 2 companies

In mid-June 2023, the Belgian chemical giant Solvay announced a split into two independent public companies. The first company will retain the Solvay name and include monotechnology facilities that produce soda ash, peroxides, silica and coatis, among others, which are assigned to the chemicals segment at Solvay, as well as a division of Special Chem. More. here

Exit from joint venture with Sibur

In early March 2023, it became known that Sibur bought out a 50 percent stake in Solvay in the joint manufacturer of polyvinyl chloride RusVinyl (Nizhny Novgorod Region). The companies agreed on the final terms of the deal, Sibur said. Read more here.

2009: Abbot pharma division sale for €4.8bn

In September 2009, it became known that the American company Abbott Laboratories signed an agreement to acquire the pharmaceutical division of the Belgian chemical-pharmaceutical conglomerate Solvay SA. The transaction amount is about 4.8 billion euros ($7 billion) in cash. Abbott will make a one-time payment of 4.5 billion euros, and the remaining 300 million euros will pay in 2011-2013. upon achievement of certain goals. The deal is Abbott's largest since 2002.

The American company sees this deal as a springboard for expanding activities in emerging markets in Eastern Europe and Asia, and also gains access to new drugs for the treatment of hypertension and Parkinson's disease. In addition, Abbott gains full control of Tricor and Trilipix, for which Abbott and Solvay are marketing partners.

Solvay Pharma's range also includes hormone therapy drugs. The company also has a small vaccine division. This direction is very important against the background of the spread of the H1N1 influenza virus. In early September 2009, the Belgian company announced the start of production of small batches of vaccine for clinical trials. It is likely that Abbott will be able to invest in this business, but it is not yet clear how quickly Solvay enterprises will be able to start industrial production of the vaccine.

According to analysts, Abbott needs to reduce its dependence on the drug for the treatment of rheumatoid arthritis Humira, whose sales in 2008 amounted to $4.5 billion, or 15% of the net profit of the American company.

Abbott managed to "replay" another contender for the acquisition of Solvay Pharma - the Swiss Nycomed, which was considered the most likely buyer^[1] the^[1]

In Russia, the company's business was represented by Solvey-Pharma LLC.

2009: Reduced revenue to €8.5 billion

The company focuses on two areas: the chemical sector, the production of plastic products. Solvay's revenue for 2009 (including the indicators sold by Solvay Pharma) is €8.5 billion (for 2008 - €9.5 billion), net profit - €516 million (€405 million).

1863: Forming a Company

The company was organized in 1863.

Notes